Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347917 | 0.88 | CYP3A4 (0.51) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL2383124 | 0.80 | CYP3A4 (0.58) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL484746 | 0.80 | KMT2A (0.64) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL11067587 | 0.78 | CYP3A4 (0.79) | CYP3A4HPGDPOLBKMT2ACA1 | |
| SCHEMBL4153927 | 0.78 | CYP3A4 (0.58) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL939482 | 0.78 | CYP3A4 (0.56) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL939484 | 0.78 | KMT2A (0.62) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL3341002 | 0.78 | NNMT (0.46) | CYP3A4HPGDPOLBKMT2APARP1 | |
| SCHEMBL31465700 | 0.77 | CYP3A4 (0.55) | CYP3A4HPGDPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL9241705 | 0.77 | TAAR1 (0.52) | CYP3A4POLBSMN1; SMN2PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003528802-A | — | — | 2003-09-30 | — | — | JP | claimed |
| US-20020025977-A1 | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives | NEUROGEN CORPORATION | 2002-02-28 | — | — | US | claimed |
| EP-1165517-A1 | N-BENZIMIDAZOLYLMETHYL- AND N-INDOLYLMETHYL-BENZAMIDES AND THEIR USE AS CRF MODULATORS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | claimed |
| US-6281237-B1 | MODULATORS OF CRF RECEPTORS AND ARE THEREFORE USEFUL FOR TREATING AFFECTIVE DISORDERS, ANXIETY, DEPRESSION, EATING DISORDERS, AND STRESS DISORDERS | NEUROGEN CORPORATION | 2001-08-28 | — | — | US | claimed |
| WO-2000059888-A1 | N-BENZIMIDAZOLYLMETHYL- AND N-INDOLYLMETHYL-BENZAMIDES AND THEIR USE AS CRF MODULATORS | NEUROGEN CORPORATION (US) | 2000-10-12 | — | — | WO | claimed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CYP3A4 4072/4885HPGD 2497/4885POLB 4540/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CYP3A4 4072/4885HPGD 2497/4885POLB 4540/4885 |
| US-20020025977-A1 | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives | CRHR1, CRHR2, HTR2C | CYP3A4 1764/4885HPGD 2387/4885POLB 4486/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | CYP3A4 4168/4885HPGD 3328/4885POLB 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.